Lambert Eaton myasthenic syndrome and pregnancies with the development of transient myasthenic syndrome in newborn

Letus present a unique clinical case course of autoimmune non paraneoplastic myasthenic syndrome of Lambert–Eaton on the background of pregnancy, in the 24 years old patient, with a 3-year history of the disease. Throughout the pregnancy, birth and early postpartum period, patient was taking a stable unmodified drug therapy, which allowed observing "natural" course for neuromuscular disease. The first trimester of pregnancy proceeded without deterioration of the myasthenic syndrome. From the middle of the second trimester (19–20 weeks gestation), and the entire third trimester until parturition, the patient's condition for neuromuscular disease has improved, which was accompanied by an increase in strength of proximal limb muscles and the positive dynamics of the basic parameters of neuromuscular transmission. Deliveries came on ime, preceeded safely through vaginal delivery, without weakness of generic forces. There was born clinically healthy male child, weighing 2970 g, growth of 52 cm (7/8 Apgar score). However , on the second day in the newborn was marked negative dynamics of muscular hypotonia, extinction of neonatal reflexes, sucking weakness, episodes of apnea, which required tube feeding and non invasive oxygen support. Neuromuscular defect was transient in character and resolved within 5–7 days with administration in the morning hours of 20 mg of prednisone parenteral. The child was discharged with full recovery of function of the neuromuscular system on the 13th day breastfed. Shortly after birth the mother appeared in a state of negative dynamics: the increased weakness of the proximal muscles of the legs and arms, deteriorated parameters of the neuromuscular conduct. By analogy with myasthenia there appeared the similar influence of pregnancy on the Lambert Eaton myasthenic syndrome: 1) improvmem of the neuromuscular disease in II–III trimester of pregnancy, 2) intact ability to birth vaginally, 3) no evidence of neuromuscular disease in newborn at birth, 4) one day delay in the development of transient neonatal myasthenic syndrome, 5) postpartum mothers deterioration that increases while breastfeeding.

1. Санадзе А.Г., Сиднев Д.В., Щербакова Н.И., Карганов М.Ю. Миастенический синдром Ламберта–Итона. Журн неврол и психиатр 2008;108(3):4–10.

2. Щербакова Н.И., Ланцова В.Б. Миастенический синдром Ламберта–Итона: особенности иммунного ответа. Механизмы развития и принципы лечения заболеваний периферической нервной системы. Под ред. Е.И. Гусева, Н.Н. Яхно, А.Г. Санадзе, Л.Ф. Касаткиной. М., 2007; с. 166–171.

3. Gilhus N.E. Lambert Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis 2011;973808:1–5.

4. Lang B., Pinto A., Glovannini F., et al. Pathogenic autoantibodies in the Lambert Eaton myasthenic syndrome. Ann NY Acad Sci 2003;998:187–95.

5. Sakai W., Nakane S., Matsuo H. Autoantibody against the presynaptic P/Qtype voltage-gated calcium channel in Lambert Eaton myasthenic syndrome. Brain Nerve 2013;65(4):441–8.

6. Vincent A., Beeson D., Lang B. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission Eur J Biochem 2000;267(23):6717–28.

7. Гехт Б.М., Ильина Н.А. Нервно-мышечные болезни. М.: Медицина, 1982; с. 314– 324.

8. Hoff J.M., Daltveit A.K., Gilhus N.E. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007;14(1):38–43.

9. Bayrak A.O., Sandikci U., Yon S.K., Onar M.K. Manifestation of Lambert Eaton myasthenic syndrome during last trimester of pregnancy. Int J Neurosci 2010;120(6 ):439–41.

10. Lambert E.H., Eaton L.M., Rooke E.D. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612–3.

11. Lecky B.R. Transient neonatal Lambert Eaton syndrome. J Neurol Neurosurg Psychiatry 2006;77(9):1094. 12. Reuner U., Kamin G., Ramantani G. et al. Transient neonatal Lambert-Eaton syndrome. J Neurol 2008;255(11):1827–8.

12. Schneider-Gold C., Wessig C., Höpker M. et al. Pregnancy and delivery of a healthy baby in autoimmune Lambert Eaton myasthenic syndrome. J Neurol 2006;253(9):1236–7.

13. Vinke M., Lehnen H. Two uncomplicated pregnancies and births in a patient with longstanding Lambert Eaton myasthenic syndrome. Geburtsh-Frauenheilkd, 2007;67:367–9.

14. Kostera-Pruszczyk A., Ryniewicz B., Rowinska-Marcinska K. et al. Lambert Eaton myasthenic syndrome in childhood. Eur J Paediatr Neurol 2009;13(2):194–6.

15. Tsao C.Y., Mendell J.R., Friemer M.L., Kissel J.T. Lambert Eaton myasthenic syndrome in children. J hild Neurol 2002;17(1):74–6.

16. Arai H., Inui K., Hashimoto K. et al. Pulmonary adenocarcinoma, Lambert–Eaton myasthenic syndrome, and voltage-gated calcium channels: a case report. J Med Case Rep 2012;5(1):281.

17. Morimoto M., Osaki T., Nagara Y. et al. Thymoma with Lambert Eaton myasthenic syndrome. Ann Thorac Surg 2010;89(6):2001–3.

18. Djelmis J., Sostarko M., Mayer D., Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002;1049(1):21–5.

19. O'carroll P., Bertorini T.E., Jacob G. et al. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSKmediated myasthenia gravis. J Clin Neuromuscul Dis 2009;11(2):69–71.

20. Ferrero S., Pretta S., Nicoletti A. et al. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;121(2):129 38.

21. Hatada Y., Munemura M., Matsuo I. et al. Myasthenic crisis in the puerperium: the possible importance of alpha-fetoprotein. Case report. Br J Obstet Gynaecol 1987;94(5):480–2.

22. Terrero A., Ramírez-Rivera J. «Seronegative» anti-MUSK positive myasthenia gravis presenting during pregnancy. Bol Asoc Med P R 2006;98(3):210–2.

23. Baslo M.B., Deymeer F., Serdaroglu P. et al. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis. Neuromuscul Disord 2006;16(7):454–8.

24. Luigetti M., Modoni A., Lo Monaco M. Low rate repetitive nerve stimulation in Lambert-Eaton myasthenic syndrome: peculiar characteristics of decremental pattern from a single-centre experience. Clin Neurophysiol 2013;124(4):819–27.

25. Heininger K., Edler C., Toyka K.V. alpha-Fetoprotein and neonatal transient myasthenia gravis. Neurology 1984;34(3):403–4.

26. Kanzaki A., Motomura M. A pregnant patient with anti-MuSK antibody positive myasthenia gravis and her infant with transient neonatal myasthenia gravis. Rinsho Shinkeigaku 2011;51(3):18891.

27. Riemersma S., Vincent A., Beeson D. et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest1996;98(10):2358–63.

28. Chieza J.T., Fleming I., Parry N., Skelton V.A. Maternal myasthenia gravis complicated by fetal arthrogryposis multiplex congenital. Int J Obstet Anesth 2011;20(1):79–82.

29. Hoff J.M., Daltveit A.K., Gilhus N.E. Artrogryposis multiplex congenita a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol Scand Suppl 2006;183:26–7.

30. Mikou F., Kaouti N., Ghazli M. et al. Severe neonatal myasthenia with arthrogryposis. J Gynecol Obstet Biol Reprod (Paris) 2003;32(7):660–2.

31. Brenner T., Beyth Y., Abramsky O. Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci USA 1980;779(6):3635–9.

32. Brenner T., Abramsky O., Lisak R.P. Influence of alpha-fetoprotein on the in vitro and in vivo immune response to acetylcholine receptor. Ann N Y Acad Sci 1981;377:208–21.